Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2002-03-14
2008-03-25
Dentz, Bernard (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C549S471000
Reexamination Certificate
active
07348359
ABSTRACT:
The present invention is directed to compounds represented by Structural Formula (I) and pharmaceutically acceptable salts, solvates and hydrates thereof: (I). The invention is also directed to pharmaceutical compositions, methods of use and methods of making compounds represented by Structural Formula (I) and pharmaceutically acceptable salts, solvates and hydrates thereof.
REFERENCES:
patent: 5801253 (1998-09-01), Klaus et al.
patent: 0 909 560 (1999-04-01), None
patent: WO 94/15902 (1994-07-01), None
patent: WO 01/19770 (2001-03-01), None
Scammells et al, Bioorganic & Medicinal Chemistry vol. 6 p. 1517-1524 (1998).
Registry No. 37894-25-0, Chem. Abstr. 89:215143 (1978).
Giguere, Vincent, et al., “Identification of a Receptor for the Morphogen Retinoic Acid,”Nature, 330: 624-629 (1987).
Petkovich, Martin, et al., “A Human Retinoic Acid Receptor Which Belongs to the Family of Nuclear Receptors,”Nature, 330: 444-450 (1987).
Evans, Ronald M., “The Steroid and Thyroid Hormone Receptor Superfamily,”Science, 240: 889-895 (1988).
Heyman, Richard A., et al., “9-Cis Retionic Acid Is a High Affinity Ligand for the Retinoid X Receptor,”Cell, 68: 397-406 (1992).
Levin, Arthur A., et al., “9-Cis Retinoic Acid Stereoisomer Binds and Activates the Nuclear Receptor RXRα,”Nature, 355: 359-361 (1992).
Mangelsdorf, David J., et al., “The Retinoid Receptors.” InThe Retinoids: Biology, Chemistry and Medicine, Michael B. Sporn, et al., eds. (NY: Raven Press), pp. 319-349 (1994).
Mangelsdorf, David J., et al., “A Direct Repeat in the Cellular Retinol-Binding Protein Type II Gene Confers Differential Regulation by RXR and RAR,”Cell, 66: 555-561 (1991).
Mukherjee, R., et al., “Human and Rat Peroxisome Proliferator Activated Receptors (PPARs) Demonstrate Similar Tissue Distribution but Different Responsiveness to PPAR Activators,”J. Steroid Biochem. Molec. Biol., 51(3/4): 157-166 (1994).
Jow, Lily and Mukherjee, Ranjan, “The Human Peroxisome Proliferator-Activated Receptor (PPAR) Subtype NUC1 Repress the Activation of hPPARα and Thyroid Hormone Recptors,”J. Biol. Chem., 270(7): 3836-3840 (1995).
Sherman, Steven, I., et al., “Central Hypothyroidism Associated with Retinoid X Receptor-Selective Ligands,”N. Engl. J. Med. 340(14): 1075-1079 (1999).
Tzukerman, Maty T., et al., “Human Estrogen Receptor Transactivational Capacity is Determined by Both Cellular and Promotor Context and Mediated by Two Functionally Distinct Intramolecular Regions,”Mol. Endo., 8: 21-30 (1994).
McDonnell, Donald P., et al., “Analysis of Estrogen Receptor Function in Vitro Reveals Three Distinct Classes of Antiestrogens,”Mol. Endo., 9: 659-669 (1995).
Casis, Raul, et al., “Synthesis of 4(1H)-Quinolones by Thermolysis of Aryl-Aminomethylene Meldrum's Acid Derivatives,”Synthetic Communications, 15(2): 125-133 (1985).
Kitamura, Masato, et al., “Asymmetric Synthesis of α-Amino β-Hydroxy Phosphonic Acids Via Binap-Ruthenium Catalyzed Hydrogenation,”Tet. Lett., 36(32): 5769-5772 (1995).
Boehm Marcus F.
Gardinier Kevin M.
Gernert Douglas L.
Grese Timothy A.
Mapes Christopher M.
Dentz Bernard
Eli Lilly and Company
Hamilton Brook Smith & Reynolds P.C.
Ligand Pharmaceuticals
LandOfFree
Retinoid X receptor modulators does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Retinoid X receptor modulators, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Retinoid X receptor modulators will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3965550